December 09, 2021
Video
Matthew Galsky, MD, discusses the future of bladder cancer research and the impact of new treatments such as immune checkpoint inhibitors and antibody-drug conjugates.
December 29, 2017
Article
The emerging arena of checkpoint inhibitors and immunotherapy in the treatment of urothelial carcinomas is explored and discussed.
November 15, 2017
Video
Matthew D. Galsky, MD, Professor of Medicine, Mount Sinai School of Medicine, discusses progression in patients with metastatic bladder cancer.
November 11, 2017
Article
Metastatic urothelial cancer is a relatively chemotherapy-sensitive malignancy. With contemporary cisplatin-based combination chemotherapy regimens, objective responses are achieved in approximately 50-60% of patients and complete radiographic responses are achieved in approximately 10-20% of patients.
January 31, 2014
Article
Matthew D. Galsky, MD, from The Mount Sinai Hospital, discusses an analysis of the distribution and geographic accessibility of prostate cancer clinical trials in the U.S.
January 08, 2014
Video
Matthew D. Galsky, MD, discusses targeted therapy treatments for bladder cancer.